Acutus Medical FY23: continuing ops revenue $7.2M, net loss $0.41 EPS; exits ablation

Acutus Medical, Inc.

2024-Q1 EPS reported -$0.06 revenue$3,625,000

Continuing ops revenue $7.2M FY (+136% YoY); Q4 $2.4M (+118% YoY).
GAAP net loss continuing ops $11.9M, EPS -$0.41; prior year net income $28.8M.
Discontinued ops loss $69.7M, including $16.4M held-for-sale loss and $21.9M restructuring.
Cash, equivalents, marketable securities $29.4M at Dec 31, 2023.
Company shifts focus to Medtronic left-heart access distribution; no further guidance.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Acutus Medical, Inc. reported fiscal year ended December 31, 2023 results: net income Net loss on continuing operations on a GAAP basis was $11.9 million for the full year ended December 31, 2023 and net lo, EPS net loss per share was $0.41.

Period: fiscal year ended December 31, 2023
Net income: Net loss on continuing operations on a GAAP basis was $11.9 million for the full year ended December 31, 2023 and net lo
EPS: net loss per share was $0.41
Result: reported results

Exact text from the filing

On April 1, 2024, the Company issued a press release announcing its financial results for the fiscal year ended December 31, 2023.

View on SEC.gov

324 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001628280-24-014025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.